Dear Ms. Tegtmeyer:

Please refer to your Supplemental New Drug Applications (sNDA’s) dated May 28, 2010 and March 18, 2011, received June 2, 2010 and March 21, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Vimpat (lacosamide) tablets, Vimpat (lacosamide) Injection, and Vimpat (lacosamide) oral solution.

We acknowledge receipt of your amendments for the following supplement sets:


The “Prior Approval” supplemental new drug application provides for revised labeling to remove all references to collapsing response mediator protein-2 (CRMP-2) based on new in vitro pharmacology studies, as well as updating the Drug Interactions and Metabolism and Elimination sections based on a new lacosamide drug interaction study with midazolam and a new in vitro study on additional CYP450 enzymes involved in lacosamide metabolism.

The “Changes Being Effected” supplemental new drug application provides for revised labeling to include new postmarketing safety information.

**APPROVAL & LABELING**

We have completed our review of these supplemental applications, and with our mutually agreed upon negotiated changes, the supplements are approved, effective on the date of this letter, for use as recommended in the enclosed.
CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert and Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).
PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

   Food and Drug Administration  
   Center for Drug Evaluation and Research  
   Office of Prescription Drug Promotion (OPDP)  
   5901-B Ammendale Road  
   Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/opacom/morechoices/fdaforms/ceder.html; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Stephanie N. Parncutt, M.H.A. Regulatory Health Project Manager, at (301) 796-4098.

Sincerely,

   {See appended electronic signature page}

   Eric Bastings, M.D.  
   Acting Director  
   Division of Neurology Products  
   Office of Drug Evaluation I  
   Center for Drug Evaluation and Research

ENCLOSURE(S):  
   Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ERIC P BASTINGS
09/25/2013